KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation von Jänne, P.A., Rybkin, I.I., Spira, A.I., Riely, G.J., Papadopoulos, K.P., Sabari, J.K., Johnson, M.L., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Leal, T.A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Ou, S.H.I.

Volltext

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers von Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

Volltext

EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US von Sabari, J.K., Yu, H.A., Mahadevia, P., Liu, Y., Demirdjian, L., Sultan, A.A., Chen, Y.H., Wang, X., Passaro, A.

Volltext

635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC von Lu, S., Zhou, C., Cho, B.C., Ono, A., Hayashi, H., Majem, M., Lee, S-H., Richardson, G., Sabari, J.K., Girard, N., Sanborn, R.E., Mansfield, A.S., Buyukkaramikli, N., Perualila, N., Acharya, S., Chandler, C., Dearden, L., Agrawal, T., Baig, M., Park, K.

Volltext

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes von Ohri, N., Jolly, S., Cooper, B., Kabarriti, R., Bodner, W.R., Guha, C., Viswanathan, S., Shum, E., Sabari, J.K., Cheng, H., Gucalp, R., Castellucci, E., Qin, A., Gadgeel, S.M., Halmos, B.

Volltext

LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis) von Le, X., Patel, J., Shum, E., Sanborn, R.E., Baik, C.S., Shu, C.A., Kim, C., Fidler, M.D., Hall, R., Hanna, N., Mohindra, N., Sabari, J.K., Heeke, S., Hernandez, M., Gray, J.E., Heymach, J.V., Saltos, A.

Volltext

MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC von Gadgeel, S., Jänne, P.A., Spira, A.I., Ou, S.-H.I., Heist, R.S., Pacheco, J.M., Johnson, M.L., Sabari, J.K., Leventakos, K., Mason, J.A., Velastegui, K., Yan, X., Chao, R., Riely, G.J.

Volltext

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (e... von Kim, T.M., Lee, S-H., Chang, G-C., Shih, J-Y., Hochmair, M.J., Sabari, J.K., Spira, A.I., Schioppa, C.A., Rose, J.B., Chioda, M., Panaccione, A., Mahadevia, P., Cho, B.C.

Volltext

LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPIL... von Girard, N., Park, K., Tang, K., Cho, B.C., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J.W., Sabari, J.K., Sanborn, R.E., Mansfield, A.S., Hung, J-Y., Popat, S., Dias, J., Bhattacharya, A., Agrawal, T., Shreeve, M., Knoblauch, R.E., Zhou, C.

Volltext

OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC von Fujiwara, Y., Reddy Ammakkanavar, N., Hollebecque, A., Murciano-Goroff, Y.R., Lee, D.H., Burns, T.F., Cassier, P., Han, J.-Y., Italiano, A., Koyama, T., Shim, B.Y., Heist, R.S., Sabari, J.K., Spira, A.I., Bodor, J., Chu, Q., Durm, G., Singhal, N., Chisamore, M.J., Fink, A., Chen, A., Willard, M.D., Oxnard, G.R., Dragnev, K.H.

Volltext

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab von Park, K., Sabari, J.K., Haura, E.B., Shu, C.A., Spira, A., Salgia, R., Reckamp, K.L., Sanborn, R.E., Govindan, R., Bauml, J.M., Curtin, J.C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R.E., Cho, B.C.

Volltext

MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC von Goldman, J.W., Cho, B.C., Cheng, S., Zhou, C., Liu, B., Yao, Y., Alip, A., Kim, Y.J., Parra, H.J. Soto, Kawamura, T., Hataji, O., Hayashi, H., Zurawski, B., Batra, U., Santos, V., Teixeira, E., Dooms, C., Alatorre-Alexander, J., Girard, N., Spira, A.I., Kim, C., Sabari, J.K., Popat, S., Park, K., Sanborn, R.E., Curtin, J.C., Zhang, J., Luo, X., Lyu, X., Bhattacharya, A., Lorenzini, P., Wortman-Vayn, H., Baig, M., Agrawal, T., Knoblauch, R.E., Mansfield, A.S.

Volltext

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12... von Riely, G.J., Ou, S-H.I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J.K., Johnson, M., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Velastegui, K., Cilliers, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Jänne, P.A.

Volltext

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC von Cho, B.C., Lee, K.H., Cho, E.K., Kim, D-W., Lee, J-S., Han, J-Y., Kim, S-W., Spira, A., Haura, E.B., Sabari, J.K., Sanborn, R.E., Bauml, J.M., Gomez, J.E., Lorenzini, P., Infante, J.R., Xie, J., Haddish-Berhane, N., Thayu, M., Knoblauch, R.E., Park, K.

Volltext

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer von Sabari, J.K., Shu, C.A., Park, K., Leighl, N., Mitchell, P., Kim, S., Lee, J., Kim, D., Viteri, S., Spira, A., Han, J., Trigo, J., Lee, C.K., Lee, K.H., Girard, N., Yang, T., Goto, K., Sanborn, R.E., Yang, J.C., Xie, J., Roshak, A., Thayu, M., Knoblauch, R.E., Cho, B.C.

Volltext